ORIGINAL ARTICLE – CANCER RESEARCH



Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma

Adrian M. Seifert^{1,2} · Julian List¹ · Max Heiduk^{1,3} · Rahel Decker¹ · Janusz von Renesse¹ · Ann-Christin Meinecke¹ · Daniela E. Aust^{4,5} · Thilo Welsch^{1,2} · Jürgen Weitz^{1,2} · Lena Seifert^{1,2}

Received: 3 July 2020 / Accepted: 18 August 2020 / Published online: 31 August 2020 $\ensuremath{\textcircled{O}}$ The Author(s) 2020

Abstract

Introduction The immunosuppressive tumor microenvironment promotes progression of pancreatic ductal adenocarcinoma (PDAC). $\gamma\delta$ T cells infiltrate the pancreatic tumor stroma and support tumorigenesis through $\alpha\beta$ T cell inhibition. Pancreatic stellate cell (PSC) activation contributes to pancreatic fibrosis in PDAC, limiting the delivery and efficacy of therapeutic agents. Whether $\gamma\delta$ T cells have direct effects on PSC activation is unknown.

Methods In this study, we analyzed tumor tissue from 68 patients with PDAC and determined the frequency and location of $\gamma\delta$ T cells using immunohistochemistry and immunofluorescence. PDAC samples from the TCGA database with low and high *TRGC2* expression were correlated with the expression of extracellular matrix genes. Further, PSCs were isolated from pancreatic tumor tissue and co-cultured with $\gamma\delta$ T cells for 48 hours and cytokine production was measured using a cytometric bead array.

Results $\gamma\delta$ T cells infiltrated the pancreatic tumor stroma and were located in proximity to PSCs. A high infiltration of $\gamma\delta$ T cells was associated with increased expression of several extracellular matrix genes in human PDAC. In vitro, $\gamma\delta$ T cells stimulated IL-6 production by PDAC-derived PSCs.

Conclusion $\gamma\delta$ T cells activated PSCs and modulation of this interaction may enhance the efficacy of combinational therapies in human PDAC.

Keywords Pancreatic cancer · Gamma-delta T cells · Pancreatic stellate cells · IL-6

Adrian M. Seifert and Julian List have contributed to this work equally.

Lena Seifert lena.seifert@ukdd.de

- ¹ Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, 01307 Dresden, Germany
- ² German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Partner Site Dresden, Heidelberg, Germany
- ³ National Center for Tumor Diseases (NCT), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, Germany
- ⁴ Department of Pathology, Medical Faculty, University Hospital Carl Gustav Carus, University of Dresden, Dresden, Germany
- ⁵ NCT Biobank Dresden, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor and projected to become the second leading cause of cancer-related deaths by 2030 (Yadav and Lowenfels 2013). One of the main reasons for its poor prognosis is the extensive fibrotic tumor stroma that impedes successful cancer therapies. Studies employing checkpoint inhibitors in PDAC have failed to elicit a sufficient response, likely due to immunosuppression mediated by the tumor stroma (Brahmer et al. 2012). The tumor stroma, harboring immune cells and pancreatic stellate cells (PSCs), accounts for up to 90% of the volume of the pancreatic tumor and comprises a complex microenvironment (Neesse et al. 2015). Oncogenic mutations alone are insufficient drivers for disease progression of PDAC, and fibrosis and inflammation are required in addition (Guerra et al. 2007). Notably, PSCs are major contributors to pancreatic fibrosis and tumorigenesis through the production of extracellular matrix (ECM) proteins and secretion of cytokines, such as transforming growth factor β (TGF- β) and interleukin-6 (IL-6) (Wu et al. 2017; Hwang et al. 2008). These factors promote fibrosis, tumor cell proliferation, angiogenesis, immunosuppression, and therapeutic resistance, leading to disease progression (Vonlaufen et al. 2008). The immune infiltrate in PDAC is rife with immunosuppressive elements that support tumorigenesis (Clark et al. 2007; Seifert et al. 2016). Antigen-presenting cells, including M2-polarized tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), support PDAC progression by inducing adaptive immune suppression (Pylayeva-Gupta et al. 2012; Bayne et al. 2012; Zhu et al. 2014). Intratumoral CD4⁺ Th2 cells and regulatory T cells (Tregs) are associated with reduced survival, whereas cytotoxic CD8⁺ T cells and CD4⁺ Th1 cells mediate tumor protection and are associated with prolonged survival in PDAC (Monte et al. 2011; Fukunaga et al. 2004; Hiraoka et al. 2006). Gamma-delta T cells (γδ T cells), a non-MHC-restricted lymphocyte subset, constitute a central source of immune-suppressive checkpoint ligands and are important regulators of effector T-cell activation in PDAC. Blockade of PD-L1 in $\gamma\delta$ T cells enhanced CD4⁺ and CD8⁺ T-cell infiltration and induced tumor protection in murine PDAC (Daley et al. 2016). Furthermore, breast cancer-infiltrating γδ T cells have the capacity to suppress dendritic cell function and, consequently, cytotoxic T-cell activation (Peng et al. 2007). In contrast, several studies in other tumors, including melanoma, renal cell, and colon cancer, suggest that $\gamma\delta$ T cells may have antitumoral effects (Gao et al. 2003; Girardi et al. 2001; Lanca and Silva-Santos 2012). Notably, in PDAC, the interaction of $\gamma\delta$ T cells with other components of the tumor stroma is unknown. In this study, we found infiltration of $\gamma\delta$ T cells in the tumor stroma of human PDAC. PDACs with a high expression of the $\gamma\delta$ T-cell-related gene TRGC2 also had increased expression of several extracellular matrix genes. $\gamma\delta$ T cells promoted IL-6 production by PDAC-derived PSCs. Our results suggest that $\gamma\delta$ T cells may have a direct effect on PSCs and that γδ T-cell modulation in PDAC may relieve local immunosuppression leading to increased invasion of cytotoxic T cells.

Materials and methods

Patient samples

 Table 1
 Clinicopathological features of PDAC patients in immunohistochemistry cohort

	Total $n = 68$	%
Age		
Median (range)	70 (36–84)	
Gender		
Male	36	52.9
Female	32	47.1
pT		
1	6	8.8
2	43	63.2
3	19	28
4	0	0
pN		
0	26	38.2
1	23	33.8
2	19	28
pМ		
0	62	91.2
1	6	8.8
UICC stage		
Ι	17	25
II	28	41.2
III	17	25
IV	6	8.8
Neoadjuvant treatment		
Yes	3	4.4
No	52	76.5
Unknown	13	19.1

Dresden. A serial section from each specimen was stained with H&E for histologic evaluation. The clinical stages of tumors were determined according to the tumor-nodemetastasis (TNM) classification system by the Union For International Cancer Control (UICC; Edition 8). Adjacent non-tumor tissue was used as normal pancreas. Patients' characteristics are shown in (Table 1).

Immunohistochemistry and immunofluorescence

Frozen tissue sections were rehydrated and blocked [5% goat serum (Sigma-Aldrich), 1% BSA, 1.5 M Tris HCl] for 30 min, as previously described (Seifert et al. 2016). Anti- $\gamma\delta$ TCR (Biolegend), anti- α -SMA, and anti-Cytokeratin 19 (both abcam) were applied at 4 °C overnight. Secondary antibodies against Mouse IgG labeled with Alexa Flour 633, Rabbit IgG labeled with Alexa Fluor 568 (all Thermofisher) were used. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, Vector Labs) and embedded in Faramount Mounting Medium (Agilent

Dako). Images were acquired on a confocal Leica SP5 MP. For immunohistochemistry, anti- $\gamma\delta$ TCR was applied for 12 h, followed by incubation with secondary antibodies for 30 min. Purified Mouse IgG1 was used as isotype control. ImmPACTTM DAB Peroxidase (Vector Labs) was used according to the manufacturer's instructions. Slides were imaged on Invitrogen EVOS FL Auto Imaging System (Thermo Fisher Scientific). Quantification was performed by assessing ten hotspots as high-power fields (HPF; 20×) per slide.

In vitro $\gamma\delta$ T-cell/PSC co-culture

Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation over Biocoll Separating Solution (Merck). $\gamma\delta$ T cells were selected and expanded from PBMCs according to an established protocol by adding zoledronate (5 µM) and IL-2 (1000 IU/mL) to the culture medium (Kondo et al. 2011). Half of the medium was exchanged every 3 days and zoledronate was deprived consequently. After 14 days of culture, the frequency of $\gamma\delta$ T cells was assessed by flow cytometry using mAbs directed against CD45 (HI30), CD3 (SK7), CD4 (RPA-T4), CD8 (SK1), and TCR γδ (B1) (all BD Biosciences). Human pancreatic stellate cells (PSCs) were isolated from pancreatic tumor tissue obtained during pancreatic surgery at our institution from patients with resectable pancreatic adenocarcinomas and cultured, as previously published (Vonlaufen et al. 2010). The purity of the PSCs was assessed by morphology and demonstration of α SMA expression. 7.5 × 10⁴ PSCs were plated alone or with expanded $\gamma\delta$ T cells (1:2 ratio) in 12-well plates in triplicate. After 48 h, supernatant was harvested and analyzed by cytometric bead array (CBA; BD Biosciences).

Flow cytometry

Single-cell suspensions were stained with mAbs directed against CD45 (HI30), CD3 (SK7), CD4 (RPA-T4), CD8 (SK1), and TCR $\gamma\delta$ (B1, all BD Biosciences). For intracellular staining, cells were stimulated with phorbol 12-myristate 13-acetate (PMA, 50 ng/mL) and ionomycin (750 ng/mL) for 4 h at 37 °C, 5% CO2 in the presence of 1 mg/mL brefeldin A (BD Biosciences). Surface staining was performed, and cells were fixed and permeabilized with the BD Cytofix/Cytoperm Kit and stained for IL-6 (MQ2-6A3, BD Biosciences). Flow cytometry was carried out on the LSR Fortessa flow cytometer (BD Biosciences). Data were analyzed using FlowJo v10 (Treestar, Ashland, OR).

Cytometric bead array

Supernatant was harvested and analyzed using a cytometric bead array according to the manufacturer's protocol (BD Biosciences).

TCGA data analysis

FPKM values from human PDAC samples were obtained from the TCGA Data Portal (https://tcga-data.nci.nih.gov). Of the pancreatic cancer samples from the TCGA database (n = 179), we analyzed only PDAC (n = 146). A heatmap was created using heatmapper (https://www.heatmapper.ca).

Statistical analysis

Data are shown as mean \pm SEM or median. Unpaired, twotailed Student's *t* test or one-way ANOVA comparisons were performed as applicable. GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA) was used. $P \le 0.05$ was considered significant.

Results

$\gamma\delta$ T cells infiltrate human PDAC

To investigate the role of $\gamma\delta$ T cells in human PDAC, we stained normal pancreas and PDAC samples for the $\gamma\delta$ T-cell receptor by immunohistochemistry (Fig. 1a). Normal pancreas had little infiltration of $\gamma\delta$ T cells, whereas intratumoral $\gamma\delta$ T cells were present in most PDAC patients with a heterogeneous distribution (Fig. 1b). However, the presence of $\gamma\delta$ T cells was not associated with tumor size, lymphnode metastasis, and UICC stage (Fig. 1c).

High $\gamma\delta$ T-cell infiltration is associated with fibrosis in PDAC

 $\gamma\delta$ T cells were mostly located in the pancreatic tumor stroma, whereas a minor fraction of $\gamma\delta$ T cells was present in the ductal area (Fig. 2a, b). We next investigated PDAC samples from the TCGA database with high *TRGC2* expression and found a strong correlation with the expression of several ECM-related genes (Fig. 2c).

$\gamma\delta$ T cells are located in proximity to PSCs in the pancreatic tumor stroma

Using immunofluorescence staining for the $\gamma\delta$ T-cell receptor and alpha-smooth muscle actin (α SMA), a differentiation marker for activated PSCs, we found that $\gamma\delta$ T cells were located near PSCs in the pancreatic tumor stroma (Fig. 3a).



Fig. 1 $\gamma\delta$ T cells infiltrate human PDAC. **a** Frozen sections of human PDAC (*n*=68) and adjacent normal pancreas (*n*=8) were tested for the expression of the $\gamma\delta$ T-cell receptor ($\gamma\delta$ TCR). Representative images are shown. Scale bar, 100 µm. **b** Quantification of $\gamma\delta$ TCR⁺

cells per high-power field (HPF). **c** Number of $\gamma\delta$ TCR⁺ cells per HPF correlated with T (left), N (middle), and UICC stages (right). Each point represents data from one patient. Data, median, unpaired *t* test, or one-way ANOVA. **P*<0.05

Consistent with this observation, PDAC samples from the TCGA database with high *TRGC2* expression also had increased *ACTA2* (α SMA) expression compared to samples with low *TRGC2* expression (Fig. 3b).

$\gamma\delta$ T cells activate PSCs and stimulate their IL-6 production

To further investigate the effect of $\gamma\delta$ T cells on PSCs, we co-cultured $\gamma\delta$ T cells with PDAC-derived PSCs. PSCs were isolated from pancreatic tumor tissue obtained during surgery from patients with resectable pancreatic adenocarcinomas and their purity was assessed by α SMA expression (Fig. 4a). Using a cytometric bead array (CBA), we measured cytokine production after 48 h. IL-6 production by PSCs was increased after co-culture with $\gamma\delta$ T cells compared to the monoculture of PSCs alone (Fig. 4b). Notably, intracellular staining showed that IL-6 was derived from PSCs exclusively and not $\gamma\delta$ T cells (Fig. 4c). Further analysis of the TCGA database revealed a significant correlation of *IL6* with high *TRGC2* expression compared to *TRGC2* low PDAC samples (Fig. 4d).

Discussion

PDAC is characterized by a dense fibrotic tumor stroma that surrounds tumor cells, compromising the efficacy of antitumor therapies and leading to poor patient survival (Watt and Kocher 2013; Feig et al. 2012). $\gamma\delta$ T cells regulate effector T-cell activation in PDAC. $\gamma\delta$ T-cell depletion was protective against murine PDAC and resulted in increased infiltration, activation, and Th1 polarization of $\alpha\beta$ T cells (Daley et al. 2016). In this study, we found the infiltration of $\gamma\delta$ T cells in the tumor stroma of human PDAC, particularly in close proximity to PSCs. $\gamma\delta$ T-cell infiltration, based on *TRGC2* gene expression, correlated with several ECM genes.

PSCs have been demonstrated to play an important role in fibrogenesis and tumorigenesis in PDAC (Apte et al. 2013). These myofibroblast-like cells secrete ECM proteins as well as many proinflammatory cytokines and are responsible for the desmoplastic reaction. However, little is known about the interaction of PSCs with immune cells in the tumor stroma. Previously, an increased migration of CD8⁺ T cells towards activated, CXCL12-secreting PSCs was shown (Ene-Obong et al. 2013). Additionally, PSC-conditioned media attracted increased numbers of cytotoxic CD8⁺ and CD4⁺ T cells in vitro, suggesting that PSCs are important regulators of immune cell infiltration into the pancreatic tumor stroma.



Fig.2 High $\gamma\delta$ T-cell infiltration is associated with fibrosis in PDAC. **a** Frozen sections of human PDAC (*n*=68) were tested for the expression of the $\gamma\delta$ T-cell receptor ($\gamma\delta$ TCR) and analyzed by their intratumoral location (duct vs. stroma). Representative images are shown. Scale bar, 100 µm. **b** Quantification of $\gamma\delta$ TCR⁺ cells per

high-power field (HPF). Each point represents data from one patient. Data, median, unpaired *t* test. ***P<0.001 (c) Heatmap showing low and high tertiles of *TRGC2* expression and indicated extracellular matrix genes in human PDAC samples from the TCGA database. Row, indicated gene; columns; color key indicates row Z-score



Fig. 3 $\gamma\delta$ T cells are located in proximity to PSCs in the pancreatic tumor stroma. (a) Frozen human PDAC specimens were stained for alpha-smooth muscle actin (α SMA), $\gamma\delta$ TCR and CK19 by immunofluorescence. Representative image is shown. Scale bar, 25 µm. **b**

Correlation between the high and low tertiles of *TRGC2* expression and *ACTA2* expression was tested in human PDAC samples from the TCGA database. Each point represents data from one patient. Data, median, unpaired *t* test. *P < 0.05



Fig. 4 $\gamma\delta$ T cells activate PSCs and stimulate their IL-6 production. **a** PSCs were tested for alpha-smooth muscle actin (α SMA) expression by immunofluorescence. Representative image is shown. Scale bar, 25 μ m. **b** PSCs (7.5×10⁴) were plated alone or together with expanded $\gamma\delta$ T cells (1:2 ratio) in 12-well plates and IL-6 expression was measured in the supernatant by cytometric bead array (CBA). **c**

 $\gamma\delta$ T cells and PSCs were tested for IL-6 expression. Representative histograms and quantification are shown. **d** Correlation between the high and low tertiles of *TRGC2* expression and *IL6* expression was tested in human PDAC samples from the TCGA database. Each point represents data from one patient. Data, mean or median, unpaired *t* test, or one-way ANOVA. ***P*<0.01, *****P*<0.0001

Furthermore, PSCs have been shown to promote differentiation of the MDSC phenotype through IL-6 and suppress T-cell proliferation (Mace et al. 2013).

Immunotherapeutic strategies have failed to improve overall survival for PDAC patients (Brahmer et al. 2012). However, immunotherapy in combination with stromal depletion has led to reduced tumor size and prolonged survival in murine PDAC. While in transgenic $Ptfla^{cre/+}$; LSL- $Kras^{G12D/+}$; $Tgfbr2^{flox/flox}$ (PKT) mice, deletion of α SMA⁺ myofibroblasts did not enhance gemcitabine efficacy, treatment with anti-CTLA-4 decreased disease acceleration and prolonged survival (Ozdemir et al. 2014). Notably, FAP⁺ stromal cells are the principal source of CXCL12 in PDAC. Blockade of the CXCL12–CXCR4 axis induced T-cell infiltration and enhanced the antitumor effects of anti-CTLA-4 and anti-PD-L1 treatment in murine PDAC (Feig et al. 2013). Currently, therapeutic strategies are being investigated in which stromal depletion is pursued.

Generally, the interaction between immune cells and PSCs in the pancreatic tumor microenvironment has not

been well defined. Mast cells have been shown to contribute to PSC proliferation through IL-13 and tryptase, contributing to PDAC development (Ma et al. 2013). Additionally, IL-15 enhanced natural killer cell cytotoxicity towards PSCs in vitro (Audenaerde et al. 2017).

In this study, we found that $\gamma\delta$ T cells activated PSCs and stimulated their IL-6 production. In PDAC patients, increased IL-6 serum levels have been correlated with tumor size and the presence of liver metastases (Talar-Wojnarowska et al. 2009; Ebrahimi et al. 2004). Notably, PSCderived IL-6 directly enhanced STAT3-dependent progression of PanINs towards invasive carcinomas (Nagathihalli et al. 2016). Furthermore, IL-6 promoted PDAC tumorigenesis through downstream activation of the STAT3/SOCS3 signaling pathway (Lesina et al. 2011). In colorectal cancer, IL-6/IL-11-dependent STAT3 activation in cancer-associated fibroblasts promoted tumor development and also correlated with poor prognosis (Heichler et al. 2019). Our study provides evidence that $\gamma\delta$ T cells activate PSCs to secrete IL-6, which may, in turn, promote PDAC development and progression. A pre-clinical study indicated that targeting IL-6 may enhance the antitumor efficacy of PD-L1 blockade in PDAC through increased T-cell activation and infiltration (Mace et al. 2018). Furthermore, IL-6 in colorectal cancer and ovarian cancer ascites with a high concentration of IL-6 has been shown to polarize M2 macrophages (Chen et al. 2018; Duluc et al. 2007). Several studies have shown that macrophages play an important role in tumorigenesis depending on their phenotype-M1 macrophages are associated with an inflammatory response and antitumor immunity, whereas M2 macrophages promote angiogenesis and immunosuppression and enhance tumor progression (Sica and Mantovani 2012). In PDAC, M2-polarized macrophages have tumor-promoting effects by releasing immunosuppressive cytokines and inducing Th2 and regulatory T-cell differentiation of CD4⁺ T cells (Liu et al. 2013).

In conclusion, $\gamma\delta$ T cells are novel stimuli of PSC secreted IL-6 contributing to their role as critical regulators of immunosuppression and tumor progression in PDAC. Modulation or inhibition of $\gamma\delta$ T cells alone or in combination with IL-6-receptor blockade may enhance the efficacy of chemotherapy and immunotherapy in PDAC.

Acknowledgements This work was supported by the German Research Foundation (DFG), the Ernst-Jung Stiftung, the Monika Kutzner Stiftung, the German Cancer Consortium (DKTK), and the Medical Faculty Carl Gustav Carus TU Dresden. We thank the Core Facility Cellular Imaging (CFCI) TU Dresden for their support.

Author contributions Study concept and design: AMS and LS; acquisition of data: JL, MH, and ACM; analysis and interpretation of data: AMS, JL, MH, DEA, and LS; writing of manuscript: AMS and LS; critical review: JL, MH, RD, JR, TW, DEA, and JW; study supervision: AMS and LS.

Funding Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest The authors have declared that no conflict of interest exists.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Apte MV, Wilson JS, Lugea A, Pandol SJ (2013) A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 144(6):1210–1219
- Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ et al (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822–835
- Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465
- Chen L, Wang S, Wang Y, Zhang W, Ma K, Hu C et al (2018) IL-6 influences the polarization of macrophages and the formation and growth of colorectal tumor. Oncotarget 9(25):17443–17454
- Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67(19):9518–9527
- Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G et al (2016) Gammadelta T Cells support pancreatic oncogenesis by restraining alphabeta T cell activation. Cell 166(6):1485–9915
- De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H et al (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478
- Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J et al (2007) Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophagelike cells. Blood 110(13):4319–4330
- Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R (2004) Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101(12):2727–2736
- Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC et al (2013) Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 145(5):1121–1132
- Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA (2012) The pancreas cancer microenvironment. Clin Cancer Res 18(16):4266–4276
- Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS et al (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110(50):20212–20217
- Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T et al (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1):e26–31
- Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH et al (2003) Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198(3):433–442
- Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R et al (2001) Regulation of cutaneous malignancy by gammadelta T cells. Science 294(5542):605–609
- Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11(3):291–302
- Heichler C, Scheibe K, Schmied A, Geppert CI, Schmid B, Wirtz S et al (2019) STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut 2:19

- Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12(18):5423–5434
- Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A et al (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68(3):918–926
- Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H et al (2011) Expansion of human peripheral blood gammadelta T cells using zoledronate. J Vis Exp 1:55
- Lanca T, Silva-Santos B (2012) The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology 1(5):717–725
- Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G et al (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19(4):456–469
- Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P et al (2013) M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 93(7):844–854
- Ma Y, Hwang RF, Logsdon CD, Ullrich SE (2013) Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res 73(13):3927–3937
- Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS et al (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73(10):3007–3018
- Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S et al (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67(2):320–332
- Nagathihalli NS, Castellanos JA, VanSaun MN, Dai X, Ambrose M, Guo Q et al (2016) Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget 7(40):65982–65992
- Neesse A, Algul H, Tuveson DA, Gress TM (2015) Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut 64(9):1476–1484
- Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719–734
- Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF (2007) Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27(2):334–348

- Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6):836–847
- Seifert L, Werba G, Tiwari S, Giao Ly NN, Alothman S, Alqunaibit D et al (2016) The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532(7598):245–249
- Seifert AM, Reiche C, Heiduk M, Tannert A, Meinecke AC, Baier S et al (2020) Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene 5:9–23
- Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122(3):787–795
- Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E (2009) Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54(3):683–689
- Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ et al (2017) Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget 8(34):56968–56979
- Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR et al (2008) Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 68(7):2085–2093
- Vonlaufen A, Phillips PA, Yang L, Xu Z, Fiala-Beer E, Zhang X et al (2010) Isolation of quiescent human pancreatic stellate cells: a promising in vitro tool for studies of human pancreatic stellate cell biology. Pancreatology 10(4):434–443
- Watt J, Kocher HM (2013) The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. Oncoimmunology 2(12):e26788
- Wu Q, Tian Y, Zhang J, Zhang H, Gu F, Lu Y et al (2017) Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. Oncotarget 8(60):102721–102738
- Yadav D, Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144(6):1252–1261
- Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J et al (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18):5057–5069

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.